Article Per Year (5 Year)
p-Index From 2019 - 2024
0.562
P-Index
This Author published in this journals
All Journal Narra J
Mehrdad Amir-Behghadami
Iranian Center of Excellence in Health Management, Department of Health Service Management, School of Management and Medical Informatics, Tabriz University of Medical Sciences, Tabriz, Iran
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search
Journal : Narra J

 1 
Acceptance and willingness to purchase a hypothetical COVID-19 vaccine in a region under Shariah law: A cross-sectional study in Aceh, Indonesia Muhammad A. Rayhan; Mudatsir Mudatsir; Nurjannah Nurjannah; Ichsan Ichsan; Mehrdad Amir-Behghadami; Yousef S. Khader; Ai Koyanagi; Ranjit Sah; Sandro G. Viveiros-Rosa; Mohammed A. Mamun; Yohannes K. Lemu; Assarag Bouchra; Laure SG. Linguissi; Aamer Ikram; Dina E. Sallam; Konstantinos Parperis; Uwe Wollina; Marius Rademaker; Sandro Vento; Said Usman
Narra J Vol. 2 No. 2 (2022): August 2022
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v2i2.85

Abstract

Vaccines are urgently needed to control the coronavirus disease 2019 (COVID-19) pandemic. The aim of this study was to determine the acceptance of and willingness to purchase a hypothetical COVID-19 vaccine in the general population of Aceh, a holistic Shariah law implementation province in Indonesia. An online cross-sectional study was conducted using a quota sampling technique between 1 to 24 September 2021. To determine hypothetical vaccine acceptance, respondents were asked if they were willing to accept vaccines with combinations of either 50% or 95% effectiveness and either 5% or 20% risk of adverse effects. Willingness to purchase was assessed by asking whether the participants would pay for such vaccines at certain price points. Logistic regression analysis was used to assess the associated determinants. Out of 377 respondents included in the final analysis, 86.5% were willing to accept a COVID-19 vaccine with 95% effectiveness and 5% adverse effects. The acceptance rate dropped to 45.1% if the risk of adverse effects was 20%. Vaccines with 50% effectiveness and 5% adverse effects were acceptable to 42.2% but the acceptance went down to 17.2% if the risk of adverse effects increased to 20%. Multivariate analysis found that men were twice as likely to accept a vaccine with 95% effectiveness and 5% adverse effects compared to females (aOR: 2.01; 95% CI 1.05–3.86). We found that 156/377 (41.3%) of respondents were willing to purchase a COVID-19 vaccine and of these participants 71.1% were willing to pay between Indonesian Rupiah (IDR) 50,000–150,000 (US$ 3.33–10.00). In conclusion, the acceptance rate of a hypothetical COVID-19 vaccine varied based on effectiveness and the risk of adverse effects.
Monkeypox: Immune response, vaccination and preventive efforts Youdiil Ophinni; Andri Frediansyah; Salin Sirinam; Dewi Megawati; Ana M. Stoian; Seyi S. Enitan; Richard Y. Akele; Ranjit Sah; Krit Pongpirul; Ziad Abdeen; Sevda Aghayeva; Aamer Ikram; Yohannes Kebede; Uwe Wollina; Kannan Subbaram; Ai Koyanagi; Abdulwahed Al Serouri; H. Blaise Nguendo-Yongsi; Jeffrey Edwards; Dina E. Sallam; Yousef Khader; Sandro G. Viveiros-Rosa; Ziad A. Memish; Mehrdad Amir-Behghadami; Sandro Vento; Marius Rademaker; Malik Sallam
Narra J Vol. 2 No. 3 (2022): December 2022
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v2i3.90

Abstract

Infectious threats to humans are continuously emerging. The 2022 worldwide monkeypox outbreak is the latest of these threats with the virus rapidly spreading to 106 countries by the end of September 2022. The burden of the ongoing monkeypox outbreak is manifested by 68,000 cumulative confirmed cases and 26 deaths. Although monkeypox is usually a self-limited disease, patients can suffer from extremely painful skin lesions and complications can occur with reported mortalities. The antigenic similarity between the smallpox virus (variola virus) and monkeypox virus can be utilized to prevent monkeypox using smallpox vaccines; treatment is also based on antivirals initially designed to treat smallpox. However, further studies are needed to fully decipher the immune response to monkeypox virus and the immune evasion mechanisms. In this review we provide an up-to-date discussion of the current state of knowledge regarding monkeypox virus with a special focus on innate immune response, immune evasion mechanisms and vaccination against the virus.
Monkeypox: Immune response, vaccination and preventive efforts Youdiil Ophinni; Andri Frediansyah; Salin Sirinam; Dewi Megawati; Ana M. Stoian; Seyi S. Enitan; Richard Y. Akele; Ranjit Sah; Krit Pongpirul; Ziad Abdeen; Sevda Aghayeva; Aamer Ikram; Yohannes Kebede; Uwe Wollina; Kannan Subbaram; Ai Koyanagi; Abdulwahed Al Serouri; H. Blaise Nguendo-Yongsi; Jeffrey Edwards; Dina E. Sallam; Yousef Khader; Sandro G. Viveiros-Rosa; Ziad A. Memish; Mehrdad Amir-Behghadami; Sandro Vento; Marius Rademaker; Malik Sallam
Narra J Vol. 2 No. 3 (2022): December 2022
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v2i3.90

Abstract

Infectious threats to humans are continuously emerging. The 2022 worldwide monkeypox outbreak is the latest of these threats with the virus rapidly spreading to 106 countries by the end of September 2022. The burden of the ongoing monkeypox outbreak is manifested by 68,000 cumulative confirmed cases and 26 deaths. Although monkeypox is usually a self-limited disease, patients can suffer from extremely painful skin lesions and complications can occur with reported mortalities. The antigenic similarity between the smallpox virus (variola virus) and monkeypox virus can be utilized to prevent monkeypox using smallpox vaccines; treatment is also based on antivirals initially designed to treat smallpox. However, further studies are needed to fully decipher the immune response to monkeypox virus and the immune evasion mechanisms. In this review we provide an up-to-date discussion of the current state of knowledge regarding monkeypox virus with a special focus on innate immune response, immune evasion mechanisms and vaccination against the virus.
Co-Authors Aamer Ikram Aamer Ikram Abdulwahed Al Serouri Ai Koyanagi Ai Koyanagi Ana M. Stoian Andri Frediansyah Assarag Bouchra Dewi Megawati Dina E. Sallam Dina E. Sallam H. Blaise Nguendo-Yongsi Ichsan Ichsan Jeffrey Edwards Kannan Subbaram Konstantinos Parperis Krit Pongpirul Laure SG. Linguissi Malik Sallam Malik Sallam Marius Rademaker Marius Rademaker Mohammed A. Mamun Mudatsir Mudatsir Muhammad A. Rayhan Nurjannah Nurjannah Ranjit Sah Ranjit Sah Richard Y. Akele Said Usman Salin Sirinam Sandro G. Viveiros-Rosa Sandro G. Viveiros-Rosa Sandro Vento Sevda Aghayeva Seyi S. Enitan Uwe Wollina Uwe Wollina Yohannes K. Lemu Yohannes Kebede Youdiil Ophinni Yousef Khader Yousef S. Khader Ziad A. Memish Ziad Abdeen